Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones January 9, 2025 CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab - Read More December 11, 2024 CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature - Read More December 10, 2024 CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference - Read More Load MoreLoadingMeet us at the following conferences & events J.P. Morgan Healthcare Conference 2025 Jan 13 - Jan 16, 2025 San Francisco, USA Read More
